Acumen Pharmaceuticals, Inc. (ABOS)

Over the past six months, Acumen Pharmaceuticals, Inc.'s stock price has fluctuated. As of November 13, 2025, the share price was $1.81, a 30.65% decline over the past year. The stock was down 26.89% over the past 30 days as of November 20, 2025. In May 2025, the company reported its first-quarter 2025 financial results, highlighting the full enrollment of the Phase 2 ALTITUDE-AD study, with topline results expected in late 2026. The company's cash position as of March 31, 2025, was $197.9 million, expected to fund operations into early 2027. In September 2025, the stock reached an 11-month high, influenced by data from rivals' Alzheimer's treatments. On November 12, 2025, the company announced it would report its third-quarter 2025 financial results.

Acumen Pharmaceuticals, Inc. does not have commercialized products subject to traditional demand seasonality. Seasonality in relation to ABOS typically refers to stock market seasonality rather than demand for the company's future products.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for Alzheimer's disease, operating in the Healthcare sector. Their primary product candidate, Sabirnetug (ACU193), is a humanized monoclonal antibody targeting toxic soluble amyloid-beta oligomers. Sabirnetug has completed Phase 1 and is in Phase 2 clinical trials. Acumen is also exploring a subcutaneous formulation and collaborating with JCR Pharmaceuticals for enhanced brain delivery.

Acumen Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts, with some sources indicating a headquarters in Charlottesville, Virginia, and clinical operations in Carmel, Indiana.

Acumen Pharmaceuticals' brand reputation has been shaped by its progress in clinical trials for Sabirnetug (ACU193). Positive results from the Phase 1 trial and advancement to Phase 2 have contributed positively. Collaborations with Halozyme, Inc. and JCR Pharmaceuticals enhance its reputation for strategic partnerships and innovation. Future trial results will be critical to its standing.

Acumen Pharmaceuticals, Inc. has significant institutional ownership, with 146 institutional owners and shareholders holding between 58.99% and 71.01% of the company's stock. Major institutional owners include Ra Capital Management, L.P., Sands Capital Ventures, LLC, and Franklin Resources Inc. Individual investors hold about 23.78% of the company, with Robert D. Hardie being the largest individual shareholder. Insiders hold approximately 9.30% to 17.23% of the stock.